57470-78-7
中文名称
盐酸塞利洛尔
英文名称
Celiprolol hydrochloride
CAS
57470-78-7
EINECS 编号
260-752-2
分子式
C20H34ClN3O4
MDL 编号
MFCD00941500
分子量
415.95
MOL 文件
57470-78-7.mol
更新日期
2024/04/12 14:20:59
57470-78-7 结构式
基本信息
中文别名
3-[3-乙酰-4-(3-叔丁胺基)-2-羟基丙氧基]苯基-1,1-二乙基脲盐酸盐盐酸塞利洛尔
2,2,3,3,4,4,5,5,6-九溴联苯醚
英文别名
3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea hydrochlorideCELIPROLOL HYDROCHLORIDE
3-(3-acetil-4-(3-tert-butilamino-2-hidroxipropoxi)fenil)-1,1-dietilureahcl
3-(3-acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-1,1-ure
3-(3-acetyl-4-(3-tert-butylamino-2-hydroxypropoxy)phenyl)-1,1-diethylharnsto
3-(3-acetyl-4-(3-tert-butylamino-2-hydroxypropoxy)phenyl)-1,1-diethylureahyd
celiprololclorhidrato
celiprololhydrochlorid
clorhidratodeceliprolol
ffhcl
rhc-5320a
selectrol
st1396clorhidrato
st1396hydrochlorid
st1396hydrochloride
Celipolol Hydrochloride
3-[3-acetyl-4-[3-[(tert-butyl)amino]-2-hydroxypropoxy]phenyl]-1,1-diethyluronium chloride
Urea, N-3-acetyl-4-3-(1,1-dimethylethyl)amino-2-hydroxypropoxyphenyl-N,N-diethyl-, monohydrochloride
CELIPOLOLHYDROCHLORIDE(SUBJECTTOPATENTFREE)
Celectol
所属类别
原料药：抗心律失常药物理化学性质
熔点197-200°C (dec.)
RTECS号YR6560000
储存条件Refrigerator
溶解度Freely soluble in water and in methanol, soluble in ethanol (96 per cent), very slightly soluble in methylene chloride.
形态neat
颜色白色至灰白色
水溶解性Soluble in ethanol, methanol and water
安全数据
警示词警告
危险性描述H303
毒性LD50 in male mice, rats (mg/kg): 56.2, 68.3 i.v.; 1834, 3826 orally (Wendtlandt, Pittner)
盐酸塞利洛尔价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/01/16 | S5923 | 盐酸塞利洛尔 Celiprolol hydrochloride | 57470-78-7 | 2mg | 795.34元 |
| 2024/01/16 | S5923 | Celiprolol hydrochloride | 57470-78-7 | 10mg | 1777.23元 |
常见问题列表
生物活性
Celiprolol是β1-adrenoceptor拮抗剂，具有部分β2受体激动剂活性。靶点
β1-andrenoceptor
体内研究
Celiprolol (5 or 50 mg/kg; p.o. every day for 12 weeks) has a moderate antihypertensive action at the dose of 50 mg/kg, and significantly reduces media smooth muscle hypertrophy of the mesenteric artery in SHR.
| Animal Model: | Male spontaneously hypertensive rats (SHR) and age-matched Wistar-Kyoto (WKY) rats (8 weeks old) |
| Dosage: | 5, 50 mg/kg |
| Administration: | P.o. every day (administered in drinking water) for 12 weeks |
| Result: |
Attenuated the rise in blood pressure significantly at the dose of 50 mg/kg in SHR.
Did not significantly affect absolute heart or body weights. Reduced the average medial thickness of the mesenteric artery in SHR. |